Online citations, reference lists, and bibliographies.
← Back to Search

Promising Investigational Drug Candidates In Phase I And Phase II Clinical Trials For Mesothelioma

A. Guazzelli, Emyr Bakker, K. Tian, C. Demonacos, M. Krstic-Demonacos, L. Mutti
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
ABSTRACT Introduction: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to poor prognosis. Within this article potential targets to improve the quality of life of the patients and assessment of further avenues for research are discussed. Areas covered: This review highlights emerging therapies currently under investigation for malignant mesothelioma with a specific focus on phase I and phase II clinical trials. Three main areas are discussed: immunotherapy (immune checkpoint blockade and cancer vaccines, among others), multitargeted therapy (such as targeting pro-angiogenic genes) and gene therapy (such as suicide gene therapy). For each, clinical trials are described to detail the current or past investigations at phase I and II. Expert opinion: The approach of applying existing treatments from other cancers does not show significant benefit, with the most promising outcome being an increase in survival of 2.7 months following combination of chemotherapy with bevacizumab. It is our opinion that the hypoxic microenvironment, the role of the stroma, and the metabolic status of mesothelioma should all be assessed and characterised to aid in the development of new treatments to improve patient outcomes.
This paper references
10.1158/1535-7163.MCT-13-0926
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
S. Golfier (2014)
10.1016/j.pharmthera.2013.03.004
Monoclonal antibody-based therapies in cancer: advances and challenges.
P. Sapra (2013)
10.1111/jcmm.13143
Selective blockade of B7‐H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma
Liang Mao (2017)
10.1016/j.bbamcr.2015.08.003
The role of microenvironment and immunity in drug response in leukemia.
Emyr Bakker (2016)
10.1016/j.critrevonc.2016.08.011
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
G. Bronte (2016)
10.1016/0190-9622(91)70102-8
Tumor necrosis factor.
P. Wakefield (1991)
10.1186/1479-5876-11-187
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
P. Schuberth (2013)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
[Dendritic cell-based therapeutic cancer vaccines].
M. Rizzo (2016)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
Useful information on mesothelin and its place in mesothelioma therapy by Villena-Vargas and colleagues
10.18632/genesandcancer.124
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment
Noushin Nabavi (2016)
10.3389/fonc.2016.00239
Recent Advances in Immunotherapy in Metastatic NSCLC
P. Bansal (2016)
111In-Labeled CHX-A''-DTPA-conjugated MORAb-009, a chimeric monoclonal antibody directed against mesothelin. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD)2004
A. Chopra (2004)
Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers
10.1007/s11864-008-0067-z
Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis
H. Yang (2008)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1038/nrc3792
FAK in cancer: mechanistic findings and clinical applications
Florian J. Sulzmaier (2014)
10.1200/JCO.2009.27.3649
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
V. Gregorc (2010)
Cancer, Leukemia Group B. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia
R Govindan (2005)
Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma.
C. Doyle (2015)
10.2165/00128413-199811430-00013
Gene therapy in mesothelioma
U. Hengge (1998)
10.1586/era.12.132
Ipilimumab in melanoma
P. Specenier (2012)
10.4172/2157-7412.1000139
Suicide Gene Therapy for Cancer - Current Strategies.
P. Zarogoulidis (2013)
10.1007/s00262-010-0871-8
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
L. Krug (2010)
10.1634/theoncologist.2015-0507
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
D. Kazandjian (2016)
Institute between 1986 and 2006
C Boutin (2008)
10.1097/JTO.0b013e3181ec18db
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
10.1016/S1556-0864(16)30330-6
CRS‐207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial: 208O_PR
T. Jahan (2016)
Wilms' tumor gene 1): biology and cancer immunotherapy
H Sugiyama
10.1002/0471142905.hg1308s14
Cancer Vaccines
T. Greten (2001)
Gene therapy for mesothelioma. Current treatment options in oncology
A Vachani (2011)
10.1016/J.LUNGCAN.2006.01.007
Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.
A. Powell (2006)
10.1053/j.seminoncol.2012.02.008
Clinical development of Listeria monocytogenes-based immunotherapies.
D. Le (2012)
10.1200/JCO.2016.71.2109
Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov.
A. Tan (2017)
10.1038/sj.cr.7310025
Therapy of cancer by cytokines mediated by gene therapy approach
Cheng Qian (2006)
10.1016/j.immuni.2013.07.004
Dendritic-cell-based therapeutic cancer vaccines.
K. Palucka (2013)
10.1136/jclinpath-2011-200631
Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma
Y. Enomoto (2012)
10.1016/J.JTHO.2016.11.300
OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies
J. Quispel-Janssen (2017)
10.1136/bcr-2016-216426
Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis
Rubens Chang (2016)
10.1378/CHEST.128.5.3382
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
F. Demirag (2005)
10.1164/RCCM.200501-057OC
Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.
J. Hegmans (2005)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
111In-Labeled CHX-A''-DTPA-conjugated MORAb-009, a chimeric monoclonal antibody directed against mesothelin. Molecular Imaging and Contrast Agent Database (MICAD)
A. Chopra (2004)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
Tremelimumab for patients with chemotherapyresistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
L Calabro (2013)
10.1007/s10637-014-0196-0
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
Y. Fujisaka (2014)
10.1158/1078-0432.CCR-10-2275
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
R. Hassan (2010)
Antibody targeting of TGFbeta in cancer patients
S Lonning (2011)
10.1136/bmj.h988
Cancer vaccines
L. Butterfield (2015)
doubleblind, placebo-controlled, randomized phase II trial of gemcitabine/ cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma
H L Kindler
Development of an Fcenhanced anti-B7-H3 monoclonal antibody with potent antitumor activity
D Loo (2012)
10.1007/s12038-017-9665-x
Immune modulation by dendritic-cell-based cancer vaccines
C. Kumar (2017)
10.1016/j.ccm.2012.12.005
Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.
A. Haas (2013)
10.1126/science.270.5238.985
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
10.1200/JCO.2014.59.4358
Immune Checkpoint Blockade in Cancer Therapy.
M. Postow (2015)
10.1097/01.JTO.0000263706.23579.35
Cytokine gene therapy for malignant pleural mesothelioma.
A. Vachani (2007)
10.1158/1078-0432.CCR-09-0062
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
R. Kreitman (2009)
10.2147/BTT.S2383
Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
C. Porta (2008)
10.1289/ehp.1002845
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park (2011)
10.1016/j.it.2008.02.011
CTLA-4 trafficking and surface expression.
Elke Valk (2008)
10.1371/journal.pone.0161779
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Mark Selby (2016)
10.1165/rcmb.2013-0472TR
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
R. Wong (2014)
10.1634/THEONCOLOGIST.12-6-713
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
M. Cohen (2007)
10.1038/sj.cgt.7700935
Gene therapy for malignant mesothelioma: beyond the infant years
R. Most (2006)
10.1158/1078-0432.CCR-10-3126
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
M. Cheever (2011)
Adoptive TCell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma Current Status and Future Outlook
R Wu (2012)
10.2147/OTT.S40527
Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
C. Della Pepa (2014)
10.1002/cncr.28875
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
R. Hassan (2014)
10.1158/1078-0432.CCR-14-0804
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
10.1080/21678707.2017.1325358
Current and prospective pharmacotherapies for the treatment of pleural mesothelioma
Emyr Bakker (2017)
10.1016/S1535-6108(03)00113-2
Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.
W. Ho (2003)
10.1016/J.LUNGCAN.2005.10.016
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
A. Destro (2006)
•• Detailed review of immunotherapy in mesothelioma
10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N
Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma
C. Boutin (1994)
10.1002/cncr.23617
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
[Table, 111In-Labeled CHX-A''-DTPA–conjugated MORAb-009, a chimeric monoclonal antibody directed against mesothelin].
A. Chopra (2012)
•• General overview of immune checkpoint blockade in cancer by Postow and colleagues
10.1164/rccm.200909-1465OC
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
J. Hegmans (2010)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
10.1097/JTO.0b013e318191520c
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
S. Ramalingam (2009)
10.1177/1758834015615514
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
G. Wurz (2016)
• Useful article on DC-based vaccines by Palucka and colleagues
10.1158/1078-0432.CCR-16-0714
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma
Julia A. Beaver (2017)
10.1200/JCO.2005.14.167
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
W. Kelly (2005)
10.1158/1078-0432.CCR-07-0403
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
D. Sterman (2007)
10.3390/vaccines3020344
Whole Tumor Antigen Vaccines: Where Are We?
C. Chiang (2015)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
10.1093/jjco/hyp194
WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
H. Sugiyama (2010)
10.1002/jso.21901
Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations
O. Rena (2011)
10.1038/nrc3002
Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene
V. Huff (2011)
Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ case reports
R Chang (2016)
Selective blockade of B7H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma
L Mao (2017)
10.1016/j.lungcan.2011.11.014
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2012)
10.1158/1078-0432.CCR-12-0715
Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
D. Loo (2012)
10.1016/j.canlet.2012.10.014
Tumor necrosis factor.
W. Chu (2013)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1002/cncr.23552
High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
J. Klapper (2008)
10.1158/1078-0432.CCR-05-0405
Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy
D. Sterman (2005)
10.1158/1078-0432.CCR-16-1387
Nivolumab in the Treatment of Hodgkin Lymphoma
S. Ansell (2016)
10.1073/pnas.1320318110
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer
Christine Feig (2013)
10.1016/J.CEB.2007.02.010
Receptor tyrosine kinases: mechanisms of activation and signaling.
S. Hubbard (2007)
10.4161/cam.4.1.11361
What's the place of immunotherapy in malignant mesothelioma treatments?
M. Grégoire (2010)
Long-term follow-up of patients with malignant pleural mesothelioma receiving highdose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy
DH Sterman (2005)
10.1073/pnas.0813101106
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
C. Carpenito (2009)
10.1016/B978-0-12-407190-2.00007-1
Therapeutic cancer vaccines: past, present, and future.
C. Guo (2013)
Suicide Gene Therapy for Cancer – Current Strategies. Journal of genetic syndrome & gene therapy 2013;4:16849
P Zarogoulidis (2013)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1186/s12916-016-0623-5
Cancer immunotherapy: the beginning of the end of cancer?
S. Farkona (2016)
Antibody targeting of TGF-beta in cancer patients
S Lonning (2011)
Phase II study of asparagineglycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma
V Gregorc (2010)
Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacology & therapeutics
P Sapra (2013)
10.1172/JCI32446
Adoptive T cell therapy for cancer in the clinic.
C. June (2007)
10.1164/rccm.201508-1573OC
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
R. Cornelissen (2016)
Antibody targeting of TGF-beta in cancer patients. Current pharmaceutical biotechnology
S Lonning (2011)
10.1592/phco.31.8.813
Cancer Immunotherapy: Sipuleucel‐T and Beyond
Aimee E. Hammerstrom (2011)
10.1097/PPO.0b013e31824d4465
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
R. Wu (2012)
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and EXPERT OPINION ON INVESTIGATIONAL DRUGS 943 molecular study with clinico-pathological correlations
A Destro (2006)
10.1158/1078-0432.CCR-11-1920
The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
D. Lee (2012)
10.1517/14712598.2015.1116515
Tremelimumab for the treatment of malignant mesothelioma
A. Guazzelli (2015)
Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Current treatment options in oncology
H Yang (2008)
10.1007/s12094-011-0720-z
Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer
G. Koukourakis (2011)
• Important study on bevacizumab in mesothelioma
10.1158/2326-6066.CIR-15-0064
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
L. Emens (2015)
10.2174/138920111798808392
Antibody targeting of TGF-β in cancer patients.
S. Lonning (2011)
10.3978/j.issn.2225-319X.2012.10.03
Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.
Jonathan Villena-Vargas (2012)
10.1111/j.1476-5381.2009.00190.x
Therapeutic antibodies: successes, limitations and hopes for the future
P. Chames (2009)
10.1016/S2213-2600(15)00092-2
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
10.1016/j.cell.2008.07.001
TGFβ in Cancer
J. Massagué (2008)
Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Antonio J. Grillo-López (1999)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
TGFbeta in Cancer
J Massague (2008)
10.4161/onci.26218
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
J. Stevenson (2013)
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Raffit Hassan (2007)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma
C. Demonacos
10.1017/erm.2012.6
Molecular pathogenesis of malignant mesothelioma.
P. Rascoe (2012)
10.1001/jamaoncol.2015.3931
The Use of Superlatives in Cancer Research.
M. Abola (2016)
10.2147/BTT.S3509
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
B. Escudier (2008)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.2217/imt-2016-0123
Anti-CTLA-4 therapy for malignant mesothelioma.
A. Guazzelli (2017)
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific redirected T cells
PC Schuberth (2013)
Molecular Imaging and Contrast Agent Database (MICAD)
10.1183/16000617.0063-2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
A. Bibby (2016)



This paper is referenced by
10.1515/pp-2019-0010
MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma
O. Sgarbura (2019)
10.1080/13543784.2019.1638363
What can independent research for mesothelioma achieve to treat this orphan disease?
A. Guazzelli (2019)
10.2174/1573394713666170907160734
Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
B. Doonan (2017)
Pleura and Peritoneum
Naoual Bakrin (2018)
10.1007/978-981-15-4735-5_14
Reduction of Antitumor Immunity Caused by Asbestos Exposure
Naoko Kumagai-Takei (2020)
10.3390/ijms20020429
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
A. Guazzelli (2019)
10.1007/978-981-15-4735-5
Allergy and Immunotoxicology in Occupational Health - The Next Step
T. Otsuki (2020)
10.3389/fonc.2018.00091
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
Marika Rossini (2018)
10.1186/s12967-018-1650-0
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification
K. Tian (2018)
10.1016/j.lungcan.2018.10.015
Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
R. Tranchant (2018)
10.2147/IJN.S186344
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
E. Cova (2019)
Semantic Scholar Logo Some data provided by SemanticScholar